Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
C-OPTIMISE: Certolizumab Pegol Maintenance in axSpA
NCT02505542Phase 3Completed
- Sponsor
- UCB
- Start
- Jul 2015
- Primary completion
- Feb 2019
- Modality
- Antibody Fragments, Polymer-based Nanoparticles
- Countries
- 14
01
Overview
Phase 3, randomised, double-blind trial of certolizumab pegol in axial spondyloarthritis (axSpA) (4 arms), sponsored by UCB. Primary endpoint: Percentage of Participants in Part B Who Did Not Experienced a Flare. Started Jul 2015; status: completed.
02
Drugs
certolizumab pegol
03
Conditions
axial spondyloarthritis (axSpA)
Beyond the preview
Go deeper on NCT02505542.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02505542.